Stemina Biomarker Discovery’s recent study on cardiovascular toxicity was published in the Toxicological Sciences journal this month, the company announced recently.

According to a release, the study suggests that the results of the drug screening test (Cardio quickPredict) could provide drug developers with an early, highly accurate and more comprehensive evaluation of cardiovascular toxicity. (Cardiovascular toxicity includes damage to the heart due to toxin-induced electrophysiological abnormalities or/and muscle damage.)

“Regulatory agencies have begun to push for the development of human systems as alternatives to animal testing or as complementary methods for studying the potential health effects of drug-induced cardiovascular toxicity,” Stemina CEO Elizabeth Donley said in a statement.

In the study, Stemina used human cardiomyocytes (hiPSC-CM) produced by FUJIFILM Cellular Dynamics.